Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase 1/2 4

Status

Terminated 10Unknown 9Completed 8Recruiting 7Withdrawn 5Active not recruiting 5Not yet recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 184Carcinoma, Non-Small-Cell Lung 142Multiple Myeloma 119Prostatic Neoplasms 116Colorectal Neoplasms 75Leukemia, Myeloid, Acute 74Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 65Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 63Pancreatic Neoplasms 55Ovarian Neoplasms 49Sarcoma 45Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Interventions

tilsotolimod 1sacituzumab govitecan 1pembrolizumab 1niraparib 1encorafenib 1cobimetinib 1binimetinib 1atezolizumab 1Nivolumab 1Ipilimumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Solid Tumor × Clear all
NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Gilead Sciences

Phase 2 Active not recruiting
53 enrolled
Other solid neoplasm

Solid Tumor

NCT05642780 2025-10-14

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Klus Pharma Inc.

Phase 2 Active not recruiting
240 enrolled
Other solid neoplasm

Solid Tumor

NCT03839342 2025-02-03

BEAVER

University Health Network, Toronto

Phase 2 Active not recruiting
26 enrolled
Other solid neoplasm

Solid Tumor

NCT04185831 2024-08-22

MEGALiT

Uppsala University Hospital

Phase 2 Active not recruiting
167 enrolled
Other solid neoplasm

Solid Tumor

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Idera Pharmaceuticals, Inc.

Phase 2 Active not recruiting
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡